Chardan lowered the firm’s price target on Crispr Therapeutics to $110 from $123 and keeps a Buy rating on the shares after its Q2 results. The firm is updating its model based on the probability-adjusted modeling of key franchises, raising its FY23 EPS view to ($4.65) from ($5.73) but cutting its FY24 view to ($8.21) from $6.72).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP: